Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BriaCell TherapeuticsBCTXW 29 12-1 Month Momentum % is N/A% as of Sep. 22, 2026. GuruFocus rates BCTXW with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,352 Biotechnology companies, BriaCell Therapeutics ranks worse than 84.76% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-22), BriaCell Therapeutics's 12-1 Month Momentum % is N/A%.
The industry rank for BriaCell Therapeutics's 12-1 Month Momentum % or its related term are showing as below:
BCTXW's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -20.52 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BriaCell Therapeutics 12-1 Month Momentum % Related Terms
BCTXW vs VRTX, REGN, MRNA: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, BriaCell Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BriaCell Therapeutics 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BriaCell Therapeutics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BriaCell Therapeutics (BCTXW) has a 12-1 Month Momentum % of N/A% as of Sep. 22, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on BriaCell Therapeutics and its competitors. According to the industry distribution chart, BriaCell Therapeutics ranks #1146 out of 1352 companies in the Biotechnology industry, placing it in the top 84.8%.
Is BriaCell Therapeutics' 12-1 Month Momentum % too high?
BriaCell Therapeutics' current 12-1 Month Momentum % is N/A%. Based on the distribution chart, BriaCell Therapeutics ranks #1146 out of 1352 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BriaCell Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BriaCell Therapeutics ranks #1146 out of 1352 companies for 12-1 Month Momentum %. This places BriaCell Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (BCTXW) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. BriaCell Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For BriaCell Therapeutics (BCTXW), the current 12-1 Month Momentum % is N/A% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company based in Canada that develops targeted immunotherapies for cancer. Its lead program, Bria-IMT, is a cell-based immunotherapy in late-stage clinical development for advanced breast cancer, and is being studied in combination with immune checkpoint inhibitors. The company is also developing Bria-OTS, a personalized off-the-shelf immunotherapy platform intended for breast and prostate cancers, and Bria-OTS+ and Bria-IMT-based approaches for other tumor types. BriaCell conducts its clinical trials primarily in the United States, often in collaboration with academic and research institutions, and has no approved products or product revenue; it funds operations through equity financings, research grants, and partnership arrangements. The company's goal is to advance its immunotherapy candidates through clinical trials toward regulatory approval and eventual commercialization.
29GF Score
Get the complete analysis for BCTXW
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCTXW has been successfully added to your 
